and is the only prescription eye drop approved for this use. The US Food and Drug Administration rejected Xiidra in October, asking for more trial data and further product quality information.

The case for GLP-1 drugs like Ozempic possibly causing blindness is building. A new paper out this week describes several people who developed eye conditions soon after they began taking ...

Mathrubhumi Media School students launch a powerful anti-drug poster campaign in Kerala, tackling addiction`s impact on youth ...

This new approach, described in a paper in the journal Advanced Materials, prolongs the drug's effect from six hours when it is delivered via an eye drop to up to seven weeks with a single ...

Bradley Katz, MD, PhD “We as well as other concerned physicians are also asking FDA to mandate a post-marketing survey of these drugs to find the true incidence of eye complications associated ...

Qlaris Bio is seeing double when it comes to phase 2 wins for its eye drug, hitting the primary endpoints in trials that both spanned primary open angle glaucoma (POAG) and ocular hypertension (OHT).

The other two subjects developed other eye conditions. “Although a causal link between these drugs and observed complications cannot be established, these findings cannot rule out the ...

Alnylam has said it will not proceed with a clinical trial of its RNAi drug vutrisiran in the rare eye disorder Stargardt disease – at least for now – tying its decision to President Joe Biden ...